Gwen Lomberk1, Angela J Mathison, Adrienne Grzenda, Raul Urrutia. 1. Laboratory of Chromatin Dynamics and Epigenetics, Gastroenterology Research Unit, Departments of Biochemistry and Molecular Biology, Biophysics and Medicine, Mayo Clinic, Rochester, MN 55901, USA.
Abstract
PURPOSE OF REVIEW: The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. RECENT FINDINGS: Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. SUMMARY: Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.
PURPOSE OF REVIEW: The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. RECENT FINDINGS: Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. SUMMARY: Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.
Authors: Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang Journal: Science Date: 2002-09-26 Impact factor: 47.728
Authors: Erinprit K Singh; Suchitra Ravula; Chung-Mao Pan; Po-Shen Pan; Robert C Vasko; Stephanie A Lapera; Sujith V W Weerasinghe; Mary Kay H Pflum; Shelli R McAlpine Journal: Bioorg Med Chem Lett Date: 2008-03-20 Impact factor: 2.823
Authors: M Ouaïssi; S Cabral; J Tavares; A Cordeiro da Silva; F Mathieu Daude; E Mas; Jp Bernard; B Sastre; D Lombardo; Ali Ouaissi Journal: Cancer Biol Ther Date: 2008-01-02 Impact factor: 4.742
Authors: Angela L McCleary-Wheeler; Gwen A Lomberk; Frank U Weiss; Günter Schneider; Muller Fabbri; Tara L Poshusta; Nelson J Dusetti; Sandra Baumgart; Juan L Iovanna; Volker Ellenrieder; Raul Urrutia; Martin E Fernandez-Zapico Journal: Cancer Lett Date: 2012-10-13 Impact factor: 8.679
Authors: Tewfik Hamidi; Hana Algül; Carla Eliana Cano; Maria José Sandi; Maria Inés Molejon; Marc Riemann; Ezequiel Luis Calvo; Gwen Lomberk; Jean-Charles Dagorn; Falk Weih; Raul Urrutia; Roland Michael Schmid; Juan Lucio Iovanna Journal: J Clin Invest Date: 2012-05-08 Impact factor: 14.808
Authors: Angela Mathison; Adrienne Grzenda; Gwen Lomberk; Gabriel Velez; Navtej Buttar; Pamela Tietz; Helen Hendrickson; Ann Liebl; Yuning Y Xiong; Gregory Gores; Martin Fernandez-Zapico; Nicholas F Larusso; William Faubion; Vijay H Shah; Raul Urrutia Journal: PLoS One Date: 2013-09-17 Impact factor: 3.240